# Transthyretin stabilizers and transthyretin-directed RNA interaction medicines

Drug · id `cardio:transthyretin-directed-medicines` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

Also called: Transthyretin Stabilizer; Transthyretin Stabilizers; Transthyretin-directed small interfering RNA; Transthyretin-directed RNA Interaction

Browse, organ or system: Heart  
Browse, condition area: Heart failure  

## In plain language

This page groups two kinds of medicine made for transthyretin amyloidosis, in which the protein transthyretin (TTR) forms deposits in tissues. The US labels use their own words. The tafamidis label calls the medicine a selective stabilizer of TTR, and the Attruby (acoramidis) label calls it a transthyretin stabilizer that slows the breakup of the TTR tetramer into single units. The Amvuttra (vutrisiran) label calls it a transthyretin-directed small interfering RNA that causes degradation of TTR messenger RNA, which reduces TTR protein and its deposits in tissues. Each medicine has its own page, where its label indication is recorded. This is the class page: it holds no trial results and no instructions.

## Technical summary

Class page. The name uses the RxClass class names, Transthyretin Stabilizer and Transthyretin-directed RNA Interaction; the word silencer does not appear in the labels or RxClass records read, and the Amvuttra label says small interfering RNA. No MeSH descriptor fits the group. RxClass (FDASPL source, read 2026-11-19) lists, for acoramidis, the established pharmacologic class Transthyretin Stabilizer (EPC) and the mechanism class Transthyretin Stabilizers (MoA), and for vutrisiran the classes Small Interfering RNA and Transthyretin-directed RNA Interaction (both EPC); the two medicines are filed under this page on that evidence. RxClass returned no class for tafamidis, so its filing rests on its label sentence that calls tafamidis a selective stabilizer of TTR. A small interfering RNA medicine that acts on a different target is not in this group. No trial result, dose or instruction is recorded.

## Connected pages

- Files under this front: Medicines (`cardio:front-medicines`)
- The US labels of the member medicines list the cardiomyopathy of transthyretin-mediated amyloidosis as an indication: Cardiac amyloidosis (`cardio:cardiac-amyloidosis`)
- Has subtype: Acoramidis (`cardio:acoramidis`)
- Has subtype: Tafamidis (`cardio:tafamidis`)
- Has subtype: Vutrisiran (`cardio:vutrisiran`)

## Provenance

Content hash: d393cc1ab60f574e35f6396367de11a633cf80ea699d0745fb4b3d17789fea02
Last substantive edit: 2026-11-19
Evidence last checked: 2026-11-19
